Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Inclusion Criteria:

* 18 years old ≤ age ≤ 75, regardless of gender.
* Confirmed as non-small cell lung cancer by histopathology, with pathological staging of stage Ⅱ-ⅢA.
* Received radical R0 resection of lung cancer within 2 months before enrollment, and did not receive any postoperative adjuvant therapy or preoperative neoadjuvant therapy.
* ECOG（Eastern Cooperative Oncology Group）score:0-2.
* The patient voluntarily participated in the study, agreed to cooperate with the researcher for data collection, and signed an informed consent form.

Exclusion Criteria:

* Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (Huaier group).
* Those who have difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation, and other causes of difficulty in taking oral medication.
* Non-small cell lung cancer patients who plan to receive targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, radiotherapy, synchronous radiotherapy and chemotherapy during the study period.
* The patient has a history of other new malignant tumors within 5 years.
* The expected survival time of the patient is less than half a year.
* Surgical complications that have not recovered or are accompanied by severe infections after radical resection of lung cancer.
* Pregnant or lactating women or planned pregnancy preparation.
* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect in the past one month (including but not limited to compound cantharidin capsule, cinobufagin capsule, Kangai injection, Brucea javanica injection, etc., the specific instructions shall prevail).
* The patient suffers from severe mental illness or other reasons that the researcher deems unsuitable to participate in this study.